A Study of BGM0504 in Participants with Type 2 Diabetes
Status:
RECRUITING
Trial end date:
2026-11-14
Target enrollment:
Participant gender:
Summary
This trial is conducted in China. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin and/or sulfonylureas in patients with type 2 diabetes
Phase:
PHASE3
Details
Lead Sponsor:
BrightGene Bio-Medical Technology Co., Ltd.
Collaborator:
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.